The stock is a binary catalyst play on partnership news or Phase 3 trial updates. With $8M cash lasting ~3 more quarters and no revenue, the company must secure a partnership or financing by mid-2027. Monitor EASL 2026 presentations (May 30) for any partnership announcement or data that could trigger a re-rating.
CMMB drugs
CMMB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $1.70entry
- T+1 · 6mo ago −2.35%α −1.13% · $1.66
- T+5 · 6mo ago +7.06%α +7.78% · $1.82
- T+20 · 5mo ago −2.94%α −2.08% · $1.65
- T+60 · 3mo ago +11.18%α +7.59% · $1.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The company highlighted new biomarker data from its Phase 2 SPRING trial suggesting nebokitug may benefit PSC patients with coexisting IBD, and continues pursuing partnership discussions. Cash runway extends through Q1 2027, but at a $13M market cap the stock remains a binary-option on partnership or Phase 3 outcomes.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $1.8M vs $3.3M in Q1 2025; R&D expenses fell to $0.9M from $2.5M as Phase 2 SPRING trial wound down
- Cash, equivalents and short-term deposits of $8.0M as of March 31, 2026, down from $10.4M at year-end 2025; runway through Q1 2027
- New biomarker data from SPRING trial presented at DDW 2026 and upcoming EASL 2026 suggest nebokitug modulates gut-liver inflammatory pathways relevant to PSC-IBD comorbidity
- Company continues advancing multiple partnering options for nebokitug; no definitive partnership announced
- FDA alignment on Phase 3 registration trial design for PSC previously achieved; nebokitug has FDA/EMA Orphan Drug and FDA Fast Track designations for PSC
Financial Impact
Cash burn of ~$2.4M in Q1 2026; cash runway of ~$8M expected to fund operations through Q1 2027
Risk Factors
- Cash runway only through Q1 2027; dilutive financing likely if partnership does not materialize
- No approved products or revenue; full reliance on nebokitug clinical and regulatory success
- Phase 3 PSC trial carries inherent clinical and regulatory risk; biomarker data may not translate to clinical endpoints
- Low liquidity ($13M market cap) amplifies price volatility on any news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294834 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers